Dublin, July 08, 2025 (GLOBE NEWSWIRE) — The “Schizophrenia Market Report and Forecast 2025-2034” report has been added to ResearchAndMarkets.com’s offering.
The schizophrenia market attained a value of USD 7.78 Billion in 2024. The market is further expected to grow in the forecast period of 2025-2034 at a CAGR of 5.80%, to reach USD 13.67 Billion by 2034.
Expansion of Long-Acting Injectable Antipsychotics (LAIs)
There has been an increase in the use of long-acting injectable forms of antipsychotic medication among schizophrenia patients. LAIs possess benefits like fewer relapse frequencies and increased comfort as compared to daily oral medications. LAI manufacturers and pharmaceutical companies have sought the introduction of many variations of LAI to satisfy patient demands and meet clinical requirements.
Emerging Therapies in Schizophrenia Treatment
Higher levels of expenditure in research and development for the drug and stronger comprehension of the disease are contributing to the enhancement of clinicians’ information bases. Subsequent research has resulted in indications of possible treatments that are intended to fulfill the unmet needs. Novel products such as Sumitomo Pharma/Otsuka Pharmaceuticals’ Ulotaront (SEP-363856) and others are expected to be launched during the forecast period, indicating new entrants in the treatment scenario.
Advancements in Genetic Research
Modern genetic discoveries are influencing the comprehension and management of schizophrenia. Cytogenetic, molecular, and genetic analyses have revealed possible genetic predisposing loci and pathways in cases of the disorder through genome-wide association studies (GWAS) and genetic profiling. This knowledge is fueling the advancement of molecular therapies and individualized medication, to enhance treatment outcomes as well as decrease side effects.
Rise of Digital Therapeutics
The availability of digital therapeutics is increasingly adding to the treatment of schizophrenia. These technologies provide individualized programs, which can include cognitive behavioral therapy (CBT), social skills training, and/or medication management. These tools supplement other conventional treatments and provide patients with more therapeutic assets available at any time. It also helps in improving treatment rates and results by monitoring the patient’s condition and analyzing data remotely.
The Oral Route is Anticipated to Have the Largest Market Share Based on the Route of Administration
Based on the route of administration, the schizophrenia market is divided into oral, parenteral, and others. The oral route is expected to dominate the market because of its better patient acceptance. They are easier to take than injectable medicines and, hence, promote patient compliance.
Males Lead the Market Share Based on Gender
Based on gender, the schizophrenia market is divided into male and female, with the male segment leading due to a higher prevalence of schizophrenia in males compared to females. This gender difference affects the present market scenario for schizophrenia by promoting the need for therapeutic strategies. The pharmaceutical industry and healthcare sectors are targeting men’s health in research to enhance health solutions with the view of providing better treatments for this specific audience.
Schizophrenia Market Analysis by Region
Based on regional segmentation, the schizophrenia market is categorized into key regions including the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. Among these, the United States holds the largest market share because of factors including a high percentage of healthcare spending, advanced healthcare systems, a high level of investment in research and development, and a comparatively higher incidence of schizophrenia than other parts of the world.
The well-developed pharmaceutical industry in the United States concentrates on the creation of new products for schizophrenia treatment. This dominance affects the present market situation in various ways, such as by affecting global treatment protocols, clinical research, and the incorporation of new therapeutic regimes.
Key Questions Answered in the Schizophrenia Market
- What was the schizophrenia market value in 2023?
- What is the schizophrenia market forecast outlook for 2025-2034?
- What are the regional markets covered in the report?
- What are the major factors aiding the schizophrenia market demand?
- What are the market’s major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major schizophrenia market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the schizophrenia market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- What is the market segmentation based on type?
- What is the market breakdown based on drug class?
- What is the market segmentation based on the route of administration?
- Which route of administration (oral, parenteral, others) is preferred by patients and why?
- What is the market breakup based on gender?
- What is the incidence rate of schizophrenia in males versus females, and how does it impact market strategies?
- What is the market breakup based on the distribution channel?
- Which region is expected to lead the schizophrenia market, and what are the contributing factors
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 400 |
| Forecast Period | 2025 – 2034 |
| Estimated Market Value (USD) in 2025 | $7.78 Billion |
| Forecasted Market Value (USD) by 2034 | $13.67 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
Supplier Landscape
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Eli Lilly And Company
- Sumitomo Pharma Co Ltd
- Pfizer, Inc.
- Vanda Pharmaceuticals
- Allergan, Inc.
- H. Lundbeck A/S
- Alkermes plc
- AbbVie Inc.
- Acadia Pharmaceuticals Inc.
- Boehringer Ingelheim International GmbH
- Reviva Pharmaceuticals Holdings, Inc.
- Newron Pharmaceuticals Inc.
Schizophrenia Market Segmentation
Market Breakup by Type
- Paranoid Schizophrenia
- Hebephrenic Schizophrenia
- Catatonic Schizophrenia
- Undifferentiated Schizophrenia
Market Breakup by Drug Class
- First Generation Antipsychotics
- Chlorpromazine
- Fluphenazine
- Haloperidol
- Perphenazine
- Others
- Second Generation Antipsychotics
- Aripiprazole
- Cariprazine
- Brexpiprazole
- Aripiprazole Lauroxil
- Others
- Others
Market Breakup by Route of Administration
Market Breakup by Gender
Market Breakup by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
For more information about this report visit https://www.researchandmarkets.com/r/9gsa27
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
